|
|
| | LOBELINE SULFATE Basic information |
| Product Name: | LOBELINE SULFATE | | Synonyms: | 2-(6-(2-Hydroxy-2-phenylethyl)-1-methylpiperidin-2-yl)-1-phenylethanone sulfate;2-[6-(2-hydroxy-2-phenylethyl)-1-methyl-2-piperidinyl]-1-phenyl-ethanon[2;6alpha(s)]]-theta-[2alphsulfate(2:1)(salt);bantron;lobeline,sulfate(2:1)(salt);lobelinsulfate;LOBELINE SULFATE;LOBELINE SULPHATE | | CAS: | 134-64-5 | | MF: | C44H56N2O8S | | MW: | 772.99 | | EINECS: | 205-151-8 | | Product Categories: | Alkaloids;Biochemistry;Pyridine Alkaloids | | Mol File: | 134-64-5.mol |  |
| | LOBELINE SULFATE Chemical Properties |
| Melting point | 152-154 °C | | alpha | D20 -25° (c = 2) | | density | 1.0400 (rough estimate) | | refractive index | 1.6900 (estimate) | | storage temp. | Store at -20°C | | solubility | DMSO: 100 mg/mL (129.37 mM);Ethanol: 100 mg/mL (129.37 mM) | | Water Solubility | Water: 100 mg/mL (129.37 mM) | | Merck | 5551 | | CAS DataBase Reference | 134-64-5(CAS DataBase Reference) |
| Hazard Codes | T | | Risk Statements | 23/24/25 | | Safety Statements | 45-38-36/37/39-28A | | RIDADR | 2811 | | RTECS | OJ8490170 | | HazardClass | 6.1 | | PackingGroup | III | | HS Code | 29399900 | | Toxicity | mouse,LD50,intraperitoneal,55300ug/kg (55.3mg/kg),Veterinary and Human Toxicology. Vol. 27, Pg. 1, 1985. |
| | LOBELINE SULFATE Usage And Synthesis |
| Chemical Properties | white powder | | Uses | Lobeline perturbs intra- and extra-cellular neurotransmitter levels and diminishes the in vitro and in vivo effects of psychostimulants. | | in vivo | Lobeline (0.3-3.0 mg/kg; s.c.; single dose) sulfate decreases d-methamphetamine self-administration in rats model[3].
Lobeline (3 mg/kg; s.c.; 7 times during 7 sessions) sulfate specifically decreases responding for d-Methamphetamine in a noncompetitive manner, and increases tolerance development[3].
| Animal Model: | Sprague-Dawley rats (200-250 g)[3] | | Dosage: | 0.3 mg/kg, 1.0 mg/kg, and 3.0 mg/kg for acute administration; 3 mg/kg for chronic administration | | Administration: | Subcutaneous injection; 15 min prior to measurement, or every 15 min for 7 sessions; separated by 2 intervening maintenance days of d-methamphetamine (0.05 mg/kg/infusion) self-administration | | Result: | Decreased d-methamphetamine Self-Administration. |
|
| | LOBELINE SULFATE Preparation Products And Raw materials |
|